Ken Griffin Bio Rad Laboratories, Inc. Transaction History

Citadel Advisors LLC

$505 Billion
Q3 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Rad Laboratories, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 8,400 shares of BIO stock, worth $2.78 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

8,400

Previous 8,300 1.2%

Holding current value

$2.78 Million

Previous $2.27 Million 24.01%

% of portfolio

0.0%

Previous 0.0%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$263.97 - $344.64 $5.41 Million - $7.06 Million	20,493 New	20,493 $6.86 Million
Q1 2024 May 15, 2024	BUY	$304.11 - $351.99 $4.93 Million - $5.71 Million	16,217 Added 74.21%	38,070 $13.2 Million
Q4 2023 Feb 14, 2024	BUY	$269.37 - $365.04 $4.55 Million - $6.16 Million	16,873 Added 338.82%	21,853 $7.06 Million
Q3 2023 Nov 14, 2023	SELL	$350.25 - $422.63 $13.1 Million - $15.8 Million	-37,287 Reduced 88.22%	4,980 $1.79 Million
Q2 2023 Aug 14, 2023	SELL	$359.49 - $486.4 $6.41 Million - $8.67 Million	-17,820 Reduced 29.66%	42,267 $16 Million
Q1 2023 May 15, 2023	SELL	$418.69 - $503.0 $27.6 Million - $33.1 Million	-65,877 Reduced 52.3%	60,087 $28.8 Million
Q4 2022 Feb 14, 2023	BUY	$351.71 - $456.01 $12.3 Million - $16 Million	35,034 Added 38.53%	125,964 $53 Million
Q3 2022 Nov 14, 2022	BUY	$412.59 - $563.26 $16.2 Million - $22.1 Million	39,151 Added 75.61%	90,930 $37.9 Million
Q2 2022 Aug 15, 2022	SELL	$463.67 - $597.16 $38.9 Million - $50.2 Million	-83,985 Reduced 61.86%	51,779 $25.6 Million
Q1 2022 May 16, 2022	BUY	$524.57 - $735.42 $67 Million - $93.9 Million	127,648 Added 1572.79%	135,764 $76.5 Million
Q4 2021 Feb 14, 2022	SELL	$708.84 - $794.68 $379,938 - $425,948	-536 Reduced 6.2%	8,116 $6.13 Million
Q3 2021 Nov 15, 2021	SELL	$657.71 - $825.77 $13.7 Million - $17.2 Million	-20,789 Reduced 70.61%	8,652 $6.45 Million
Q2 2021 Aug 16, 2021	BUY	$576.64 - $649.04 $14.9 Million - $16.8 Million	25,831 Added 715.54%	29,441 $19 Million
Q1 2021 May 17, 2021	BUY	$547.01 - $662.35 $1.97 Million - $2.39 Million	3,610 New	3,610 $2.06 Million
Q4 2020 Feb 16, 2021	SELL	$510.68 - $643.45 $2.42 Million - $3.06 Million	-4,748 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$454.43 - $535.6 $6.98 Million - $8.23 Million	-15,368 Reduced 76.4%	4,748 $2.45 Million
Q2 2020 Aug 14, 2020	SELL	$334.87 - $493.06 $1.74 Million - $2.56 Million	-5,202 Reduced 20.55%	20,116 $9.08 Million
Q1 2020 May 15, 2020	SELL	$320.01 - $409.07 $891,227 - $1.14 Million	-2,785 Reduced 9.91%	25,318 $8.88 Million
Q4 2019 Feb 14, 2020	SELL	$319.73 - $374.2 $30.2 Million - $35.3 Million	-94,313 Reduced 77.04%	28,103 $10.4 Million
Q3 2019 Nov 14, 2019	BUY	$304.55 - $345.24 $32.4 Million - $36.7 Million	106,261 Added 657.76%	122,416 $40.7 Million
Q2 2019 Aug 14, 2019	SELL	$286.93 - $312.59 $7.41 Million - $8.07 Million	-25,830 Reduced 61.52%	16,155 $5.05 Million
Q1 2019 May 15, 2019	BUY	$224.3 - $317.41 $4.78 Million - $6.77 Million	21,326 Added 103.23%	41,985 $0
Q4 2018 Feb 14, 2019	SELL	$220.1 - $309.0 $1.14 Million - $1.6 Million	-5,180 Reduced 20.05%	20,659 $4.8 Million
Q3 2018 Nov 13, 2018	BUY	$289.28 - $326.15 $6.23 Million - $7.03 Million	21,541 Added 501.19%	25,839 $0
Q2 2018 Aug 10, 2018	SELL	$244.1 - $303.88 $630,022 - $784,314	-2,581 Reduced 37.52%	4,298 $0
Q1 2018 May 11, 2018	SELL	$233.97 - $274.11 $41.7 Million - $48.9 Million	-178,217 Reduced 96.28%	6,879 $1.72 Million
Q4 2017 Feb 09, 2018	SELL	$216.94 - $271.3 $6.38 Million - $7.98 Million	-29,398 Reduced 13.71%	185,096 $44.2 Million
Q3 2017 Nov 09, 2017	BUY	$212.27 - $242.28 $45.5 Million - $52 Million	214,494	214,494 $47.7 Million

Others Institutions Holding BIO

# of Institutions

456

Shares Held

18.2M

Call Options Held

19.5K

Put Options Held

13.9K

View Full List

About BIO-RAD LABORATORIES, INC.

Ticker BIO
Exchange NYSE
Sector Healthcare
Industry Medical Devices
Shares Outstandng 24,633,900
Market Cap $8.14B
Description
Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, an...

More about BIO

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account